...
首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
【24h】

Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.

机译:高Km 5'-核苷酸酶(cN-II)mRNA表达在高危骨髓增生异常综合症中的临床意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We analyzed cytosolic high-Km 5'-nucleotidase (cN-II) and deoxycytidine kinase (dCK) mRNA expression in bone marrow mononuclear cells (BMMNC) of patients with high-risk myelodysplastic syndrome (MDS) using quantitative real-time polymerase chain reaction (rt-PCR). At diagnosis, the cN-II mRNA expression of patients was higher than that of healthy volunteers, but the dCK mRNA expression showed no significant difference. Patients with ara-C-containing chemotherapies whose BMMNC showed a high level of cN-II expression (greater than the median value) had shorter median overall survival (15 months versus 22 months, p<0.01) and shorter median post-chemotherapy survival (10 months versus 16 months, p=0.012). These data suggest that the expression level of cN-II mRNA might be a prognostic factor of high-risk MDS.
机译:我们使用定量实时聚合酶链反应分析了高危骨髓增生异常综合征(MDS)患者的骨髓单个核细胞(BMMNC)中的胞浆高Km 5'核苷酸酶(cN-II)和脱氧胞苷激酶(dCK)mRNA表达(rt-PCR)。诊断时,患者的cN-II mRNA表达高于健康志愿者,但dCK mRNA表达无明显差异。 BMMNC显示高水平的cN-II表达(大于中值)的含ara-C化疗的患者,中位总生存期较短(15个月对22个月,p <0.01),化疗后中位生存期较短( 10个月对16个月,p = 0.012)。这些数据表明,cN-II mRNA的表达水平可能是高危MDS的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号